The short version
Krystal Biotech built a profitable, cash-rich business on a single gene therapy approved just three years ago. The filed numbers show margins expanding sharply and a cash pile larger than a full year of revenue. The stock trades at a fraction of its own historical valuation, even as the company reported its first positive tumor data from a new cancer program six days ago. The open question is whether one commercial product can justify the price while the pipeline proves itself, or whether the pipeline is already doing more work than the market is giving it credit for.
From a rare skin disease to a cash machine
Krystal Biotech spent years as a money-losing research outfit. The company had one bet: a gene therapy called VYJUVEK, delivered directly to wounds as a topical gel, designed for patients with dystrophic epidermolysis bullosa, a genetic condition where skin blisters and tears at the slightest touch. The pivotal Phase 3 study launched in July 2020, positive results arrived in November 2021, and FDA approval followed in May 2023. That is a fast clock for a gene therapy.
What happened next is the contrast that defines this story. A company that earned nothing in 2021 reported $389 million in revenue for FY2025, with more than half of every dollar of sales falling through to profit. That margin is not typical for a pharmaceutical company at this stage. It reflects a product with almost no manufacturing middlemen: Krystal makes VYJUVEK in its own facility, which is why the Q2 2026 10-Q shows a 95% gross margin for the quarter, the share of each sales dollar left after the direct cost of making the drug. A grocery store runs at roughly a quarter of that. A 95% gross margin means the product is essentially printing money once a patient is on therapy.
Within the filed financials, that gross margin figure is the single most consequential data point for assessing whether the business has earned its current valuation.
What the Q2 2026 filing actually says
The 10-Q filed August 3, 2026 shows cumulative revenue since launch approaching a billion dollars from one drug in roughly three years. The company ended June with cash and investments exceeding a full year of revenue, more than enough to cover several years of operating expenses even before counting what the product continues to generate. That is not a company scrambling for its next funding round.
The prescriber base reached over 640 unique physicians, and the company had secured more than 730 reimbursement approvals globally, meaning insurers in those markets have agreed to pay. European launches in Spain and Italy are on track for later in 2026, opening new revenue geography. The math here is straightforward: a high-margin product, a growing prescriber base, and a balance sheet that removes financing risk from the equation entirely.
The event that changed the conversation: KB113
On October 15, 2026, Krystal reported initial proof-of-concept data for KB113, an intratumoral immunotherapy, meaning a drug injected directly into tumors, in a pilot study for patients with Gorlin syndrome, a genetic condition that causes patients to grow dozens or hundreds of basal cell carcinomas across their skin over a lifetime. In three patients, roughly half of all assessed tumors shrank by more than half, and a handful showed histologically confirmed complete responses in injected lesions, meaning a pathologist examined the tissue and found no remaining tumor. All adverse events were mild or moderate and resolved on their own.
Three patients is a tiny sample. The data cannot tell us whether this effect holds at scale, and the company said so plainly. But the FDA interaction that followed the same day, with Krystal entering discussions on advanced clinical development for KB113, is a signal that regulators see enough to engage. That is a different status than a compound sitting in a lab.
For a business built on one approved product, a second program clearing its first clinical hurdle is the kind of event that changes what the pipeline is worth, even if the math on that value remains genuinely uncertain.
What the valuation says, and what it doesn’t
The math, as we use the term at BullScope, is what filed fundamentals justify. The mood is what the market is currently paying. Here, those two readings sit in an unusual place. Our data shows the stock’s current price-to-earnings multiple sitting at the 13th percentile of its own history, cheaper relative to its own earnings, by its own historical standard, than it has been the vast majority of the time. The stock is trading at a discount to its own past, even as margins are expanding and the pipeline is producing its first oncology signal.
Goldman Sachs reinstated coverage on September 24, 2026, with a positive rating, attributed to analyst Andrea Newkirk; HC Wainwright’s Joseph Pantginis held a positive rating with a stated valuation view as of October 15. These are the attributed opinions of those analysts and their firms, reproduced here as market context only, they are not BullScope’s view and should not be read as a recommendation. What the filed numbers can say on their own is that a business earning exceptional net margins, holding more cash than a year of revenue, and sitting at the low end of its own historical valuation range is not obviously priced for its current operating performance.
The question the filing cannot answer is whether KB803 for ocular DEB lesions and KB801 for a corneal condition, both with registrational readouts expected before year-end, will extend the company’s commercial runway beyond a single indication. That answer is coming. The filing just tells us the company has the cash and the margins to wait for it.
Reading the numbers
- $119.2 million, Q2 2026 net product revenue (10-Q, June 30, 2026): This is what VYJUVEK brought in during a single quarter. A business earning at that rate for a full year would generate roughly $475 million in annual revenue. That figure matters because it sets the baseline against which any pipeline addition would be measured.
- 95% gross margin, Q2 2026: Of every dollar VYJUVEK generated, 95 cents remained after the direct cost of making the drug. A household analogy: if a bakery sold a loaf for $10 and the flour, labor, and oven cost only 50 cents, the rest is available for rent, salaries, and profit. That is roughly the economics here. It means Krystal can fund its pipeline from operations rather than from diluting shareholders.
- $1.1 billion in cash and investments, June 30, 2026: Against $175 million to $195 million in guided annual operating expenses, this is roughly five to six years of runway before the product revenue is counted. A family with $100,000 in savings and $18,000 in annual bills has the same proportional cushion. The practical meaning is that Krystal is not dependent on capital markets to reach its next clinical milestones.
- P/E at 13th percentile of own history (our data): The stock is cheaper relative to its own earnings, by its own historical standard, than it has been 87% of the time. That is not a buy signal; it is a description of where mood sits relative to math. IF earnings hold near current filed levels and IF the historical multiple were to revert toward its own median, the arithmetic would narrow that gap; IF earnings disappoint, the gap could close in the other direction. Either path depends on data not yet filed.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Krystal Biotech Q2 2026 earnings release (IR site)
- GlobeNewswire Q2 2026 results
- KB113 positive clinical data announcement, October 15, 2026 (IR site)
- Goldman Sachs coverage reinstatement, September 24, 2026 (Investing.com)
- Phase 3 GEM-3 study initiation, July 2020 (GlobeNewswire)
- GEM-3 positive topline results, November 2021 (IR site)
